Inhibition of macrophage phagocytotic activity by a receptor-targeted polymer vesicle-based drug delivery formulation of pravastatin

Journal of Cardiovascular Pharmacology

Volumn 51, Issue 3, 2008, Pages 246-252

  Broz, Pavel ^a,b   Ben Haim, Nadav ^a   Grzelakowski, Mariusz ^a   Marsch, Stephan ^a   Meier, Wolfgang ^a   Hunziker, Patrick ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b Medical Intensive Care Unit   (Switzerland)

Author keywords

Macrophages; Oxidized low density lipoprotein; Polymer vesicles; Scavenger receptors; Statins

Indexed keywords

DIMETHYLSILOXANE; POLYMER; PRAVASTATIN; SILOXANE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; CELL VACUOLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; HUMAN; HUMAN CELL; MACROPHAGE MIGRATION INHIBITION; MOUSE; MUSCLE CELL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MACROPHAGES; MICE; MUSCLE FIBERS; NANOSTRUCTURES; PHAGOCYTOSIS; POLYMERS; PRAVASTATIN; RATS; TOXICITY TESTS;

EID: 41349117048     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181624aed     Document Type: Article

References (29)

1. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
2. Casscells W, Naghavi M, Willerson JT. Vulnerable atherosclerotic plaque: A multifocal disease. Circulation. 2003;107:2072-2075.
3. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
4. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med. 1992; 326:242-250.
5. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med. 1992; 326:310-318.
6. Fuster V, Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 1994;90:2126-2146.
7. Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6:1399-1402.
8. Ni W. Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ Res. 2001;89:415-421.
9. Ray KK, Cannon CP. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects? Am J Cardiol. 2005;96:54-60.
10. Lewis SJ. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: Results of the cholesterol and recurrent events (CARE) trial. Ann Intern Med. 1998;129:681-689.
11. Sakai M. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein. Atherosclerosis. 1997;133: 51-59.
12. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21: 1712-1719.
13. Mach F. Statins as immunomodulatory agents. Circulation. 2004;109: II15-II17.
14. Bellosta S. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol. 1998;18:1671-1678.
15. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48:438-445.
16. Cannon CP. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
17. Baccante G. Pravastatin up-regulates transforming growth factor-[beta]1 in THP-1 human macrophages: effect on scavenger receptor class A expression. Biochem Biophys Res Commun. 2004;314:704-710.
18. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol. 2004;94:1140-1146.
19. Jacobson TA. The safety of aggressive statin therapy: how much can low-density lipoprotein cholesterol be lowered? Mayo Clin Proc. 2006;81: 1225-1231.
20. Broz P. Cell targeting by a generic receptor-targeted polymer nanocontainer platform. J Control Release. 2005;102:475-488.
21. Broz P. Toward intelligent nanosize bioreactors: A pH-switchable, channel-equipped, functional polymer nanocontainer. Nano Lett. 2006;6:2349-2353.
22. Discher DE, Eisenberg A. Polymer vesicles. Science. 2002;297:967-973.
23. Rigler P, Meier W. Encapsulation of fluorescent molecules by functionalized polymeric nanocontainers: investigation by confocal fluorescence imaging and fluorescence correlation spectroscopy. J Am Chem Soc. 2006;128:367-373.
24. Kaufmann P. Toxicity of statins on rat skeletal muscle mitochondria. Cell Mol Life Sci. 2006;63:2415-2425.
25. Nardin C, Hirt T, Leukel J, et al. Polymerized ABA triblock copolymer vesicles. Langmuir. 2000;16:1035-1041.
26. Vellonen KS, Honkakoski P, Urtti A. Substrates and inhibitors of efflux proteins interfere with the MTT assay in cells and may lead to under-estimation of drug toxicity. Eur J Pharm Sci. 2004;23:181-188.
27. Winkler K. Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: Baseline LDL profile determines specific mode of action. J Clin Endocrinol Metab. 2002;87:5485-5490.
28. Lukacsko P, Walters EJ, Cullen EI, et al. Efficacy of once-daily extended release lovastatin as compared to immediate-release lovastatin in patients with hypercholesterolemia. Curr Med Res Opin. 2004;20:13-18.
29. Bays HE. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin [the advicor versus other cholesterol-modulating agents trial evaluation (ADVOCATE)]. Am J Cardiol. 2003;91:667-672.